10-K: Assertio Holdings Reports 2025 Net Loss Amid ROLVEDON Integration

Assertio Holdings reports a comprehensive loss of $30.4 million in 2025, driven by strategic divestitures and ROLVEDON integration efforts, despite increased ROLVEDON sales.

Summary

• Net product sales decreased to $117.1 million in 2025 from $120.8 million in 2024.
• ROLVEDON net product sales increased by $8.1 million to $68.2 million in 2025, up from $60.1 million in 2024, primarily due to higher volume and a prior period returns reserve adjustment.
• INDOCIN net product sales decreased by $7.9 million to $18.9 million in 2025 from $26.8 million in 2024, mainly due to generic competition.
• Sympazan net product sales increased by $0.9 million to $11.3 million in 2025 from $10.5 million in 2024, driven by higher volume.
• SPRIX net product sales increased by $0.3 million to $8.0 million in 2025 from $7.6 million in 2024, due to favorable payor mix.
• Other net product sales decreased to $10.7 million in 2025 from $15.9 million in 2024, primarily due to ceasing commercialization of Otrexup in July 2025.
• Net loss from operations improved to $21.5 million in 2025 from $24.5 million in 2024.
• Comprehensive loss worsened to $30.4 million in 2025 from $21.6 million in 2024.
• Operating cash flow used $28.2 million in 2025, a significant shift from generating $26.4 million in 2024, mainly due to large distributor purchases of ROLVEDON with extended payment terms.
• Cash, cash equivalents, and short-term investments totaled $63.4 million as of December 31, 2025.
• Assertio Therapeutics was divested on May 9, 2025, resulting in an $8.2 million loss on divestiture.
• A 1-for-15 reverse stock split of common stock was effected on December 26, 2025.
• Restructuring charges increased to $2.9 million in 2025, including $1.4 million for the former CEO's severance.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a challenging period marked by declining overall sales, a significant shift to negative operating cash flow, and substantial losses from divestitures and impairments, despite growth in the key ROLVEDON product. The forward outlook includes continued declines in other product sales and potential negative impacts from regulatory changes.

Positives

• ROLVEDON net product sales increased by $8.1 million to $68.2 million in 2025, indicating growth in the lead product.
• Net loss from operations improved to $21.5 million in 2025 from $24.5 million in 2024.
• The divestiture of Assertio Therapeutics on May 9, 2025, eliminated the company's direct involvement in opioid-related litigation.
• The ROLVEDON same-day dosing trial full manuscript was accepted for publication in the peer-reviewed journal, The Oncologist, in January 2026, supporting commercialization efforts.
• Legal charges and settlements decreased by $4.7 million in 2025.
• Recognized $2.4 million of income in 2025 related to the lapsing of the statute of limitations for employee retention tax credits.

Negatives

• Total net product sales decreased to $117.1 million in 2025 from $120.8 million in 2024.
• Comprehensive loss worsened to $30.4 million in 2025 from $21.6 million in 2024.
• Operating cash flow shifted from generating $26.4 million in 2024 to using $28.2 million in 2025, primarily due to large distributor purchases with extended payment terms.
• INDOCIN net product sales decreased by $7.9 million to $18.9 million in 2025 due to generic competition.
• Ceased commercialization of Otrexup in July 2025, incurring $4.2 million in expenses.
• Recognized an $8.2 million loss on the divestiture of Assertio Therapeutics.
• Gross-to-net sales allowances on product sales increased by $50.8 million in 2025, primarily due to higher ROLVEDON sales volumes and higher contractual rebate rates.
• Royalty revenue from the CAMBIA licensing agreement decreased and is anticipated to be reduced to zero beginning in Q3 2026 due to increased generic competition.
• An impairment charge of $1.7 million was recognized for the SPRIX asset group in Q3 2025.
• Accounts receivable, net, increased by $59.5 million from December 31, 2024, to December 31, 2025, primarily due to extended payment terms for ROLVEDON sales.
• Cash and short-term investments balances declined in Q4 2025 and are anticipated to decline further in Q1 2026 due to extended payment terms.

Risks

• Inability to maintain attractive reimbursement for ROLVEDON through government programs like Medicare and Medicaid.
• Failure to successfully drive growth in ROLVEDON sales and profitability.
• Dependence on single qualified suppliers for active pharmaceutical ingredients (API) and single-source manufacturers for products, leading to potential supply risks and price increases.
• Competition from generics (INDOCIN, CAMBIA, Sympazan) and biosimilars (ROLVEDON) adversely affecting business.
• Commercial disputes impacting the commercial success of products.
• Inability to compete successfully in the pharmaceutical and biological product industry.
• Inability to negotiate acceptable pricing or obtain adequate reimbursement for products from third-party payors.
• Customer concentration, with three large national wholesale distributors representing the majority of revenues.
• Impacts from changes in laws and regulations, increased scrutiny, and investigations of the pharmaceutical industry, including drug pricing reforms and proposed CMS drug payment models.
• Potential significant liability if determined to be promoting off-label use of products.
• Macroeconomic conditions, including inflationary pressures, high interest rates, government shutdowns, and tariffs, can adversely impact business and operations.
• Failure to successfully execute business development strategies, strategic partnerships, acquisitions, or integrate acquired businesses/products.
• Existing capital resources may be insufficient to fund future operations or product acquisitions and strategic transactions.
• Inability to make interest payments on and repay the 2027 Convertible Notes.
• Incurrence of operating losses in the future.
• Impairment charges on long-lived assets if actual financial results differ materially from projections.
• Inventory write-off charges due to changes in projected demand, continuing quality issues, or other factors.
• Financial results are impacted by management's assumptions and use of estimates.
• Inability to adequately insure against product liability losses and other litigation liability.
• Limitations on the ability to use Net Operating Loss (NOL) carryforwards.
• Future product candidates may not be approved for marketing or, if approved, may not achieve market acceptance.
• Dependence on third-party contract research organizations, clinical investigators, and clinical sites to conduct clinical trials.
• Risks associated with New Drug Applications (NDAs) submitted under Section 505(b)(2) of the FDCA, including patent litigation and approval delays.
• Common stock may be delisted from The Nasdaq Capital Market if compliance with continued listing standards is not maintained.
• The market price of common stock historically has been volatile.
• Risks from proxy contests or the actions of activist shareholders.
• Risks related to unsolicited takeover attempts in the future.
• Conversions of the 2027 Convertible Notes or future sales of common stock could adversely impact stock price.
• Success is dependent in large part upon the continued services of the executive management team.
• Corporate structure may not prevent veil piercing or other similar claims.
• Inability to satisfy regulatory requirements relating to internal controls.
• Business interruptions due to natural disasters and other emergencies.
• Data breaches and cyber-attacks or other failures in telecommunications or information technology systems, including those of third-party vendors, could result in information theft, data corruption, and significant disruption.
• The use of new and evolving technologies, such as AI and ML, may pose security and other risks to sensitive data, leading to reputational harm and liability.

Future Outlook

The company does not anticipate material net product sales of ROLVEDON in the first quarter of 2026, with sales of the newly labeled ROLVEDON expected to commence at a normal volume in the second quarter of 2026. INDOCIN net product sales are expected to continue to decline in 2026 due to ongoing generic competition. Cash collections and cash and short-term investments balances are expected to decline in Q1 2026 but increase in Q2 2026. Royalty revenue from the CAMBIA licensing agreement is anticipated to be reduced to zero beginning in Q3 2026. The company expects ongoing legal expenses and settlement payments to be a significant usage of cash in 2026 and may incur additional restructuring charges. Existing cash, cash equivalents, and short-term investments are believed to be sufficient to fund operations and debt payments for the next 12 months. Potential impacts of CMS proposed new drug payment models, effective as early as October 2026, and U.S. federal administration's plans for tariffs on imported pharmaceuticals create uncertainty.

Management Comments

• "We believe we are uniquely positioned to create value for patients, providers, and shareholders in an evolving pharmaceutical landscape."
• "Our strategy is to focus on finding products that leverage our existing capabilities to build an oncology portfolio."
• "Our strategy is talent-driven and underpinned by proven commercial capabilities and a strong financial foundation."
• "Our people are at the heart of our organization."
• "Our commercial organization maximizes product impact and reach."
• "Our strong financial position enables long-term growth."
• "We plan to continue our strategy of vigorously defending ourselves in these legal matters and seeking to manage them in an efficient and cost-effective manner, while working towards a timely resolution."

Industry Context

StockSavvy.ai notes that Assertio operates in a highly competitive pharmaceutical and biological product industry, facing challenges from generic drug companies, compounding pharmacies, and biosimilars. The company's focus on oncology with ROLVEDON positions it in a high-value market, but it is subject to significant pricing pressures and regulatory changes, including government initiatives like the Inflation Reduction Act (IRA) and proposed Centers for Medicare & Medicaid Services (CMS) drug payment models aimed at lowering drug prices. The reliance on single-source suppliers and contract manufacturers is a common industry risk, exacerbated by quality control issues and demands for price increases. The increasing gross-to-net sales allowances reflect broader industry trends of managed care and rebate pressures.

Comparison to Industry Standards

• ROLVEDON, a novel long-acting G-CSF, competes with two other novel long-acting G-CSFs and six biosimilar G-CSFs marketed in the U.S.
• INDOCIN products compete with various oral opioids, transdermal opioids, local anesthetic patches, non-narcotic analgesics, local and topical analgesics, anti-arthritics, and compounded indomethacin suppositories from 503B outsourcing facilities.
• Sympazan competes with other generic and branded products in the treatment of Lennox-Gastaut Syndrome (LGS), including clobazam tablets and oral solution options, anti-seizure medications, surgery, neuromodulations, and changes in diet.
• SPRIX competes with currently marketed oral opioids, transdermal opioids, local anesthetic patches, stimulants, implantable and external infusion pumps, non-narcotic analgesics, local and topical analgesics, and anti-arthritics.
• CAMBIA competes with a number of triptans used to treat migraines, including eight generic triptans (almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, sumatriptan-naproxen, and zolmitriptan), and CGRP inhibitor products.

Management Changes

Corporate Governance

Legal Proceedings

• **Shapiro v. Assertio Holdings, Inc., et al.** (U.S. District Court, Northern District of Illinois, Case No. 1:24-cv-00169): A putative securities class action alleging false or misleading statements regarding INDOCIN sales and the Spectrum Merger's impact on profitability. The company intends to vigorously defend itself.
• **In re Assertio Holdings, Inc. Derivative Litigation** (U.S. District Court, Delaware, Case No. 1:24-cv-00383-UNA): Consolidated stockholder derivative actions alleging breach of fiduciary duties and Exchange Act violations, stayed pending the Shapiro class action.
• **Jung v. Lebel, et al.** (Delaware Chancery Court, Case No. 2024-0821) and **Jung v. Turgeon, et al.** (Delaware Chancery Court, Case No. 2024-0822): Stockholder derivative complaints against former Spectrum officers and directors, largely duplicative of other class actions, with Assertio and Spectrum having moved to dismiss.
• **Luo v. Spectrum Pharmaceuticals, Inc., et al.** (U.S. District Court, District of Nevada, Case No. 2:21-cv-01612): A putative securities class action alleging false and misleading statements regarding Spectrum's business and ROLVEDON. A $16.0 million settlement was reached, with Assertio responsible for approximately $2.7 million, and final approval granted on October 20, 2025.
• **Ayoub et al. v. Spectrum Pharmaceuticals, Inc. et al.** (U.S. District Court, Southern District of New York, Case No. 1:22-cv-10292): A consolidated class action alleging false or misleading statements about poziotinib. Mediation is scheduled for April 27, 2026, and the company intends to vigorously defend itself.
• **Enyart v. Assertio Holdings, Inc., et. al.** (Circuit Court of the Nineteenth Judicial Circuit, Lake County, Illinois, Case No. 2024LA00000842): A putative securities class action alleging misrepresentations and omissions in the registration statement for Assertio shares issued in the Spectrum Merger. A motion to dismiss was granted with leave to re-plead, and a second amended complaint was filed on March 13, 2026. The company intends to vigorously defend itself.
• **Unfair competition lawsuit against a 503B compounder**: Filed in the U.S. District Court (Southern District of Texas) regarding the compounding of 100 mg indomethacin suppositories. The dismissal was reversed on appeal, and the U.S. Supreme Court invited the U.S. Solicitor General to file a brief on January 12, 2026.
• The divestiture of Assertio Therapeutics on May 9, 2025, means the company and its current subsidiaries are no longer defendants in any opioid-related litigation.
• A settlement in principle of $1.2 million was reached with Antares in December 2025 to settle claims associated with ceasing commercialization of Otrexup.

Stakeholder Impact

• **Shareholders**: Impacted by the comprehensive loss, negative operating cash flow, reverse stock split, stock price volatility, potential dilution from convertible notes, and ongoing litigation.
• **Employees**: Affected by restructuring charges, workforce reduction, and changes in executive management, but also by new bonus plan and equity awards for leadership.
• **Customers (Wholesale Distributors)**: Engaged in large purchases of ROLVEDON with extended payment terms, impacting the company's cash flow but ensuring product supply.
• **Patients**: Continued focus on supporting patients in the oncology market with ROLVEDON. The cessation of Otrexup commercialization may impact patients relying on that product.
• **Suppliers/Manufacturers**: Dependence on single-source suppliers and contract manufacturers creates risks related to supply, quality, and potential price increase demands.
• **Creditors**: The company's ability to make payments on its 2027 Convertible Notes and potential future refinancing efforts are critical for creditors.

Next Steps

• Complete the integration of ROLVEDON into Assertio Specialty.
• Commence sales of newly labeled ROLVEDON at normal volume in the second quarter of 2026.
• Continue vigorously defending legal matters and seeking to manage them in an efficient and cost-effective manner towards timely resolution.
• Monitor and assess the potential impacts of CMS proposed new drug payment models (GLOBE and GUARD) on ROLVEDON, which could go into effect as early as October 2026.
• Monitor the scope and durability of existing and future tariffs, including potential tariffs on imported pharmaceuticals into the U.S.
• Assess the legal and business implications of demands for higher prices from API providers and suppliers.
• Continue to assess the realizability of deferred tax assets on a quarterly basis.
• Participate in mediation scheduled for April 27, 2026, for the Ayoub et al. v. Spectrum Pharmaceuticals, Inc. et al. class action.
• Attend a status conference on March 18, 2026, following the re-pleading deadline for Enyart v. Assertio Holdings, Inc., et. al.
• Mark Reisenauer is eligible for a 2026 annual equity grant, anticipated in February 2026.

Key Dates

Recommendation

Assertio Holdings faces significant headwinds, including declining overall net product sales, a shift to negative operating cash flow, and substantial legal and restructuring costs. While ROLVEDON shows growth and the company has divested opioid litigation, the future outlook for other products is negative due to generic competition. The reverse stock split and ongoing Nasdaq compliance issues add uncertainty. The company's strategy to focus on oncology and pursue acquisitions is positive, but execution risks and macroeconomic pressures remain high. A 'Hold' recommendation reflects the mixed signals: ROLVEDON's potential is offset by broader financial challenges and competitive pressures, warranting a cautious stance until clearer positive trends emerge.

Keywords

Pharmaceutical, Oncology, ROLVEDON, Eflapegrastim, Neutropenia, SEC Filing, 10-K, Financial Results, Generic Competition, Drug Development, Intellectual Property, Corporate Governance, Risk Management, Nasdaq, Reverse Stock Split, Divestiture, Capital Resources, Litigation, Cybersecurity, Sympazan, INDOCIN, SPRIX, CAMBIA